Aerie boosted as Valeant's troubled Tampa facility looks like it's coming out of rehab
Just days after Valeant $VRX and its late-stage eye drug latanoprostene bunod were turned away by the FDA for the second time after its Bausch …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
